INPEFA (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
INPEFA recently approved by FDA for treatment of heart failure
Express Scripts has determined that it will list INPEFA as a preferred product on Medicare national formularies on November 1, 2023
THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Premier Access and Premier Performance national formularies for Medicare patients on November 1, 2023. This placement will provide access to INPEFA for Express Scripts Medicare patients in plans that utilize these formularies and who meet the parameters of INPEFA’s FDA-approved indication.
“We are proud to announce this significant milestone for INPEFA and are appreciative of the expeditious steps Express Scripts has taken to make INPEFA available to patients who need it the most,” said Lonnel Coats, Lexicon’s chief executive officer. “We have been working towards this achievement and hope to continue this momentum with additional significant progress towards broad access to and coverage for INPEFA.”
On May 26, 2023, the U.S. Food and Drug Administration approved INPEFA, a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:
- heart failure or
- type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
INPEFA is currently commercially available in the U.S.
About INPEFA (sotagliflozin)
Lesen Sie auch
Discovered using Lexicon’s unique approach to gene science, INPEFA (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose reabsorption by the kidney and SGLT1 is responsible for glucose absorption in the gastrointestinal tract. INPEFA has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients.
INDICATION
INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:
- heart failure or
- type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors
IMPORTANT SAFETY INFORMATION